The University of Chicago Header Logo

Connection

Ernst Lengyel to Humans

Back to Details
This is a "connection" page, showing publications Ernst Lengyel has written about Humans.
Ernst Lengyel
Connection Strength
1.469
Humans
  1. Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. Mol Cancer Ther. 2025 Aug 01; 24(8):1252-1264.
    View in: PubMed
    Score: 0.030
  2. NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity. Nature. 2025 Sep; 645(8082):1051-1059.
    View in: PubMed
    Score: 0.030
  3. Hybrid artificial intelligence echogenic components-based diagnosis of adnexal masses on ultrasound. Med Phys. 2025 Jul; 52(7):e17983.
    View in: PubMed
    Score: 0.030
  4. Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression. Cancer Cell. 2025 Aug 11; 43(8):1495-1511.e7.
    View in: PubMed
    Score: 0.030
  5. A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer. Clin Cancer Res. 2025 Jun 03; 31(11):2230-2240.
    View in: PubMed
    Score: 0.030
  6. Molecular changes driving low-grade serous ovarian cancer and implications for treatment. Int J Gynecol Cancer. 2024 Oct; 34(10):1630-1638.
    View in: PubMed
    Score: 0.029
  7. Molecular changes driving low-grade serous ovarian cancer and implications for treatment. Int J Gynecol Cancer. 2024 10 07; 34(10):1630-1638.
    View in: PubMed
    Score: 0.029
  8. 5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer. Gynecol Oncol. 2024 03; 182:82-90.
    View in: PubMed
    Score: 0.027
  9. Adipocytes reprogram cancer cell metabolism by diverting glucose towards glycerol-3-phosphate thereby promoting metastasis. Nat Metab. 2023 09; 5(9):1563-1577.
    View in: PubMed
    Score: 0.026
  10. Diagnostic Performance of Ultrasonography-Based Risk Models in Differentiating Between Benign and Malignant Ovarian Tumors in a US Cohort. JAMA Netw Open. 2023 07 03; 6(7):e2323289.
    View in: PubMed
    Score: 0.026
  11. Decoding evolutionary trajectories of ovarian cancer metastasis. Cancer Cell. 2023 06 12; 41(6):1008-1010.
    View in: PubMed
    Score: 0.026
  12. Understanding Long-Term Survival of Patients with Ovarian Cancer-The Tumor Microenvironment Comes to the Forefront. Cancer Res. 2023 05 02; 83(9):1383-1385.
    View in: PubMed
    Score: 0.026
  13. A molecular atlas of the human postmenopausal fallopian tube and ovary from single-cell RNA and ATAC sequencing. Cell Rep. 2022 12 20; 41(12):111838.
    View in: PubMed
    Score: 0.025
  14. The adipocyte microenvironment and cancer. Cancer Metastasis Rev. 2022 09; 41(3):575-587.
    View in: PubMed
    Score: 0.025
  15. Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer. Cancer Res. 2022 01 01; 82(1):169-176.
    View in: PubMed
    Score: 0.023
  16. Change in Health-Related Socioeconomic Risk Factors and Mental Health During the Early Phase of the COVID-19 Pandemic: A National Survey of U.S. Women. J Womens Health (Larchmt). 2021 04; 30(4):502-513.
    View in: PubMed
    Score: 0.022
  17. Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. Obstet Gynecol. 2021 01 01; 137(1):108-121.
    View in: PubMed
    Score: 0.022
  18. Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer? JAMA Netw Open. 2020 08 03; 3(8):e2014184.
    View in: PubMed
    Score: 0.021
  19. Care of Transgender Persons. N Engl J Med. 2020 04 09; 382(15):1481-1482.
    View in: PubMed
    Score: 0.021
  20. Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance. Cancer Res. 2020 04 15; 80(8):1748-1761.
    View in: PubMed
    Score: 0.021
  21. Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis. Mol Cancer Ther. 2020 01; 19(1):52-62.
    View in: PubMed
    Score: 0.020
  22. New Roles for Glycogen in Tumor Progression. Trends Cancer. 2019 07; 5(7):396-399.
    View in: PubMed
    Score: 0.020
  23. The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer. Gynecol Oncol. 2019 02; 152(2):228-234.
    View in: PubMed
    Score: 0.019
  24. The Tumor Microenvironment Takes Center Stage in Ovarian Cancer Metastasis. Trends Cancer. 2018 08; 4(8):517-519.
    View in: PubMed
    Score: 0.018
  25. Cancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors. Trends Cancer. 2018 05; 4(5):374-384.
    View in: PubMed
    Score: 0.018
  26. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 2018 04; 37(17):2285-2301.
    View in: PubMed
    Score: 0.018
  27. Who are the long-term survivors of high grade serous ovarian cancer? Gynecol Oncol. 2018 01; 148(1):204-212.
    View in: PubMed
    Score: 0.018
  28. Unsaturated Fatty Acids Maintain Cancer Cell Stemness. Cell Stem Cell. 2017 03 02; 20(3):291-292.
    View in: PubMed
    Score: 0.017
  29. Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov. 2016 12; 6(12):1342-1351.
    View in: PubMed
    Score: 0.016
  30. Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform. Mol Cancer Ther. 2016 10; 15(10):2282-2293.
    View in: PubMed
    Score: 0.016
  31. Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis. Oncogene. 2015 Nov 26; 34(48):5923-32.
    View in: PubMed
    Score: 0.015
  32. Molecular pathways: trafficking of metabolic resources in the tumor microenvironment. Clin Cancer Res. 2015 Feb 15; 21(4):680-6.
    View in: PubMed
    Score: 0.015
  33. Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat Commun. 2015 Feb 05; 6:6220.
    View in: PubMed
    Score: 0.015
  34. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol. 2015 Apr; 212(4):479.e1-479.e10.
    View in: PubMed
    Score: 0.014
  35. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest. 2014 Oct; 124(10):4614-28.
    View in: PubMed
    Score: 0.014
  36. Three-dimensional modeling of ovarian cancer. Adv Drug Deliv Rev. 2014 Dec 15; 79-80:184-92.
    View in: PubMed
    Score: 0.014
  37. Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. Mol Cancer Ther. 2013 Dec; 12(12):2628-39.
    View in: PubMed
    Score: 0.013
  38. Epithelial ovarian cancer experimental models. Oncogene. 2014 Jul 10; 33(28):3619-33.
    View in: PubMed
    Score: 0.013
  39. Summary of the 2013 American Association for Cancer Research (AACR) Annual Meeting. Gynecol Oncol. 2013 Jul; 130(1):6-8.
    View in: PubMed
    Score: 0.013
  40. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta. 2013 Oct; 1831(10):1533-41.
    View in: PubMed
    Score: 0.013
  41. Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma. Gynecol Oncol. 2013 Apr; 129(1):120-3.
    View in: PubMed
    Score: 0.013
  42. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov. 2012 Dec; 2(12):1100-8.
    View in: PubMed
    Score: 0.013
  43. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2012 Jan; 119(1):61-7.
    View in: PubMed
    Score: 0.012
  44. The first line of intra-abdominal metastatic attack: breaching the mesothelial cell layer. Cancer Discov. 2011 Jul; 1(2):100-2.
    View in: PubMed
    Score: 0.011
  45. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res. 2011 Jun 15; 17(12):4042-51.
    View in: PubMed
    Score: 0.011
  46. Acute inflammatory reaction following placement of sodium hyaluronate-carboxymethylcellulose barrier in a young woman undergoing gynecologic surgery: a case report. J Reprod Med. 2011 Jan-Feb; 56(1-2):71-4.
    View in: PubMed
    Score: 0.011
  47. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res. 2011 Feb 01; 17(3):459-71.
    View in: PubMed
    Score: 0.011
  48. Ligand-independent activation of c-Met by fibronectin and a(5)ß(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene. 2011 Mar 31; 30(13):1566-76.
    View in: PubMed
    Score: 0.011
  49. Ovarian cancer development and metastasis. Am J Pathol. 2010 Sep; 177(3):1053-64.
    View in: PubMed
    Score: 0.011
  50. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia. 2010 Jan; 12(1):1-10.
    View in: PubMed
    Score: 0.010
  51. {beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol. 2009 Nov; 175(5):2184-96.
    View in: PubMed
    Score: 0.010
  52. MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle. 2009 Mar 01; 8(5):683-8.
    View in: PubMed
    Score: 0.010
  53. Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. Cancer Treat Res. 2009; 149:335-51.
    View in: PubMed
    Score: 0.010
  54. Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. Gynecol Oncol. 2008 Nov; 111(2):173-8.
    View in: PubMed
    Score: 0.009
  55. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 2008 Apr; 118(4):1367-79.
    View in: PubMed
    Score: 0.009
  56. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 2008 Apr 01; 68(7):2329-39.
    View in: PubMed
    Score: 0.009
  57. Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface. J Biol Chem. 2008 Feb 01; 283(5):2822-34.
    View in: PubMed
    Score: 0.009
  58. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer. 2007 Oct 01; 121(7):1463-72.
    View in: PubMed
    Score: 0.009
  59. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 2007 Feb 15; 67(4):1670-9.
    View in: PubMed
    Score: 0.008
  60. Tyrosine kinase mutations in human cancer. Curr Mol Med. 2007 Feb; 7(1):77-84.
    View in: PubMed
    Score: 0.008
  61. Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types. Cancer Res Commun. 2025 Nov 01; 5(11):1952-1966.
    View in: PubMed
    Score: 0.008
  62. Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. Cancer Res. 2025 Sep 15; 85(18):3471-3489.
    View in: PubMed
    Score: 0.008
  63. Adaptive immune response and PD-1/ PD-L1 status in chemotherapy treated high grade serous carcinoma is dependent on chemotherapy response score. Hum Pathol. 2025 May; 159:105800.
    View in: PubMed
    Score: 0.007
  64. Radiation-induced amphiregulin drives tumour metastasis. Nature. 2025 Jul; 643(8072):810-819.
    View in: PubMed
    Score: 0.007
  65. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 2005 Feb 10; 113(4):678-82.
    View in: PubMed
    Score: 0.007
  66. Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial. Gynecol Oncol. 2025 Mar; 194:18-24.
    View in: PubMed
    Score: 0.007
  67. A cell atlas of the human fallopian tube throughout the menstrual cycle and menopause. Nat Commun. 2025 01 03; 16(1):372.
    View in: PubMed
    Score: 0.007
  68. Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10. Cancer Cell. 2025 Jan 13; 43(1):69-85.e11.
    View in: PubMed
    Score: 0.007
  69. Systematic treatment and management of postpartum hypertension using remote patient monitoring. Pregnancy Hypertens. 2025 Mar; 39:101180.
    View in: PubMed
    Score: 0.007
  70. Isolation and characterization of Rac1 pseudogenes (psi1Rac1-psi4Rac1) in the human genome. Gene. 2004 Oct 27; 341:189-97.
    View in: PubMed
    Score: 0.007
  71. Tumor microenvironment-induced FOXM1 regulates ovarian cancer stemness. Cell Death Dis. 2024 05 28; 15(5):370.
    View in: PubMed
    Score: 0.007
  72. The glycoprotein CD147 defines miRNA-enriched extracellular vesicles that derive from cancer cells. J Extracell Vesicles. 2023 04; 12(4):e12318.
    View in: PubMed
    Score: 0.006
  73. Cancer-associated mesothelial cell-derived ANGPTL4 and STC1 promote the early steps of ovarian cancer metastasis. JCI Insight. 2023 03 22; 8(6).
    View in: PubMed
    Score: 0.006
  74. A Comparison of Obstetric Interventions and Outcomes Between Black and White Patients at an Urban Tertiary Medical Center. Reprod Sci. 2023 07; 30(7):2313-2323.
    View in: PubMed
    Score: 0.006
  75. Ovarian Masses: The Value of Acoustic Shadowing on Ultrasound Examination. J Ultrasound Med. 2023 Apr; 42(4):935-945.
    View in: PubMed
    Score: 0.006
  76. Deep Visual Proteomics defines single-cell identity and heterogeneity. Nat Biotechnol. 2022 08; 40(8):1231-1240.
    View in: PubMed
    Score: 0.006
  77. Resilience in the Face of Pandemic: The Impact of COVID-19 on the Psychologic Morbidity and Health-Related Quality of Life Among Women With Ovarian Cancer. JCO Oncol Pract. 2022 06; 18(6):e948-e957.
    View in: PubMed
    Score: 0.006
  78. Resilience: a mediator of the negative effects of pandemic-related stress on women's mental health in the USA. Arch Womens Ment Health. 2022 02; 25(1):137-146.
    View in: PubMed
    Score: 0.006
  79. Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas. Gynecol Oncol. 2021 10; 163(1):130-133.
    View in: PubMed
    Score: 0.006
  80. The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer. Cancer Res. 2021 08 01; 81(15):3985-4000.
    View in: PubMed
    Score: 0.006
  81. Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell. 2021 06 10; 184(12):3163-3177.e21.
    View in: PubMed
    Score: 0.006
  82. Ras regulation of urokinase-type plasminogen activator. Methods Enzymol. 2001; 333:105-16.
    View in: PubMed
    Score: 0.005
  83. Interpretation of Mismatch Repair Protein Immunohistochemistry in Endometrial Carcinoma Should Consider Both Lynch Syndrome Screening and Immunotherapy Susceptibility: An Illustrative Case Report. Int J Gynecol Pathol. 2020 May; 39(3):233-237.
    View in: PubMed
    Score: 0.005
  84. A streamlined mass spectrometry-based proteomics workflow for large-scale FFPE tissue analysis. J Pathol. 2020 05; 251(1):100-112.
    View in: PubMed
    Score: 0.005
  85. RADAR: differential analysis of MeRIP-seq data with a random effect model. Genome Biol. 2019 12 23; 20(1):294.
    View in: PubMed
    Score: 0.005
  86. Mesothelial Cell HIF1a Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk. Cell Rep. 2019 12 17; 29(12):4086-4098.e6.
    View in: PubMed
    Score: 0.005
  87. Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun Biol. 2019; 2:386.
    View in: PubMed
    Score: 0.005
  88. Ultrasensitive, multiplexed chemoproteomic profiling with soluble activity-dependent proximity ligation. Proc Natl Acad Sci U S A. 2019 10 22; 116(43):21493-21500.
    View in: PubMed
    Score: 0.005
  89. UVB increases urokinase-type plasminogen activator receptor (uPAR) expression. J Invest Dermatol. 1999 Jul; 113(1):69-76.
    View in: PubMed
    Score: 0.005
  90. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019 05; 569(7758):723-728.
    View in: PubMed
    Score: 0.005
  91. Mutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6. Sci Rep. 2019 03 26; 9(1):5195.
    View in: PubMed
    Score: 0.005
  92. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. 2019 06 15; 125(12):1963-1972.
    View in: PubMed
    Score: 0.005
  93. Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis. Gynecol Oncol. 2019 05; 153(2):405-415.
    View in: PubMed
    Score: 0.005
  94. SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. Mol Cancer Res. 2019 04; 17(4):870-881.
    View in: PubMed
    Score: 0.005
  95. Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. J Exp Med. 2019 01 07; 216(1):176-194.
    View in: PubMed
    Score: 0.005
  96. A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns. Biomaterials. 2019 01; 190-191:63-75.
    View in: PubMed
    Score: 0.005
  97. Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer. Cell. 2018 09 20; 175(1):159-170.e16.
    View in: PubMed
    Score: 0.005
  98. Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. Cell Metab. 2019 01 08; 29(1):141-155.e9.
    View in: PubMed
    Score: 0.005
  99. m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 2018 09; 20(9):1074-1083.
    View in: PubMed
    Score: 0.005
  100. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer. Clin Cancer Res. 2018 11 01; 24(21):5357-5367.
    View in: PubMed
    Score: 0.005
  101. An activity-dependent proximity ligation platform for spatially resolved quantification of active enzymes in single cells. Nat Commun. 2017 11 24; 8(1):1775.
    View in: PubMed
    Score: 0.004
  102. High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol. 2017 07; 146(1):153-160.
    View in: PubMed
    Score: 0.004
  103. Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. Cancer Prev Res (Phila). 2017 Apr; 10(4):255-266.
    View in: PubMed
    Score: 0.004
  104. Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity. Cancer Res. 2017 04 01; 77(7):1684-1696.
    View in: PubMed
    Score: 0.004
  105. A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth. SLAS Discov. 2017 06; 22(5):494-506.
    View in: PubMed
    Score: 0.004
  106. Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res. 1996 Nov; 2(11):1879-85.
    View in: PubMed
    Score: 0.004
  107. Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers. Cell Metab. 2016 11 08; 24(5):728-739.
    View in: PubMed
    Score: 0.004
  108. Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells. Mol Cancer Res. 2017 01; 15(1):78-92.
    View in: PubMed
    Score: 0.004
  109. Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat Commun. 2016 08 26; 7:12645.
    View in: PubMed
    Score: 0.004
  110. Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line. J Cell Biochem. 1996 Jun 01; 61(3):430-43.
    View in: PubMed
    Score: 0.004
  111. A prospective study evaluating diffusion weighted magnetic resonance imaging (DW-MRI) in the detection of peritoneal carcinomatosis in suspected gynecologic malignancies. Gynecol Oncol. 2016 07; 142(1):169-175.
    View in: PubMed
    Score: 0.004
  112. Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity. J Vis Exp. 2015 12 31; (106):e53541.
    View in: PubMed
    Score: 0.004
  113. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015 Nov; 15(11):668-79.
    View in: PubMed
    Score: 0.004
  114. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J Biol Chem. 1995 Sep 29; 270(39):23007-12.
    View in: PubMed
    Score: 0.004
  115. Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. Oncotarget. 2015 Sep 15; 6(27):23548-60.
    View in: PubMed
    Score: 0.004
  116. Stimulation of urokinase expression by TNF-alpha requires the activation of binding sites for the AP-1 and PEA3 transcription factors. Biochim Biophys Acta. 1995 Jul 20; 1268(1):65-72.
    View in: PubMed
    Score: 0.004
  117. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol. 2015 Sep; 138(3):656-62.
    View in: PubMed
    Score: 0.004
  118. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015 May 28; 521(7553):489-94.
    View in: PubMed
    Score: 0.004
  119. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. Oncotarget. 2015 May 10; 6(13):11342-56.
    View in: PubMed
    Score: 0.004
  120. MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene. 2015 Nov 26; 34(48):5857-68.
    View in: PubMed
    Score: 0.004
  121. Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. 2015 Jun; 137(3):485-9.
    View in: PubMed
    Score: 0.004
  122. Induction of M(r) 92,000 type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts. Cancer Res. 1995 Feb 15; 55(4):963-7.
    View in: PubMed
    Score: 0.004
  123. Old drug, new trick: repurposing metformin for gynecologic cancers? Gynecol Oncol. 2014 Dec; 135(3):614-21.
    View in: PubMed
    Score: 0.004
  124. WNT7A/ß-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer. Oncogene. 2015 Jun; 34(26):3452-62.
    View in: PubMed
    Score: 0.004
  125. Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis. PLoS One. 2014; 9(8):e104521.
    View in: PubMed
    Score: 0.004
  126. Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. Am J Pathol. 2014 Jan; 184(1):271-81.
    View in: PubMed
    Score: 0.003
  127. Twenty-year longitudinal study on aged people in Budapest. Z Gerontol. 1993 May-Jun; 26(3):156-62.
    View in: PubMed
    Score: 0.003
  128. miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin a5 expression. Am J Pathol. 2013 May; 182(5):1876-89.
    View in: PubMed
    Score: 0.003
  129. HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J Clin Invest. 2012 Oct; 122(10):3603-17.
    View in: PubMed
    Score: 0.003
  130. Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure. Gynecol Oncol. 2012 Nov; 127(2):316-20.
    View in: PubMed
    Score: 0.003
  131. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011 Oct 30; 17(11):1498-503.
    View in: PubMed
    Score: 0.003
  132. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011 Sep 23; 11(10):719-25.
    View in: PubMed
    Score: 0.003
  133. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer. 2012 Apr 15; 130(8):1787-97.
    View in: PubMed
    Score: 0.003
  134. FOXL2 and SOX9 distinguish the lineage of the sex cord-stromal cells in gonadoblastomas. Pediatr Dev Pathol. 2011 Sep-Oct; 14(5):391-5.
    View in: PubMed
    Score: 0.003
  135. A phase II, single-arm study of the anti-a5ß1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol. 2011 May 01; 121(2):273-9.
    View in: PubMed
    Score: 0.003
  136. The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma. Gynecol Oncol. 2011 Apr; 121(1):218-23.
    View in: PubMed
    Score: 0.003
  137. CD95 promotes tumour growth. Nature. 2010 May 27; 465(7297):492-6.
    View in: PubMed
    Score: 0.003
  138. The Müllerian HOXA10 gene promotes growth of ovarian surface epithelial cells by stimulating epithelial-stromal interactions. Mol Cell Endocrinol. 2010 Apr 12; 317(1-2):112-9.
    View in: PubMed
    Score: 0.003
  139. The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer. Fertil Steril. 2010 Sep; 94(4):1212-1217.
    View in: PubMed
    Score: 0.002
  140. Rac1 and Rho contribute to the migratory and invasive phenotype associated with somatic E-cadherin mutation. Hum Mol Genet. 2009 Oct 01; 18(19):3632-44.
    View in: PubMed
    Score: 0.002
  141. Up-regulation of alpha5-integrin by E-cadherin loss in hypoxia and its key role in the migration of extravillous trophoblast cells during early implantation. Endocrinology. 2009 Sep; 150(9):4306-15.
    View in: PubMed
    Score: 0.002
  142. A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol. 2009 Jan; 17(1):57-67.
    View in: PubMed
    Score: 0.002
  143. A special key for unlocking the door to targeted therapies of breast cancer. ScientificWorldJournal. 2008 Sep 21; 8:905-8.
    View in: PubMed
    Score: 0.002
  144. Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer. Gynecol Oncol. 2008 Dec; 111(3):537-9.
    View in: PubMed
    Score: 0.002
  145. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008 Apr 01; 22(7):894-907.
    View in: PubMed
    Score: 0.002
  146. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle. 2007 Nov 01; 6(21):2585-90.
    View in: PubMed
    Score: 0.002
  147. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. Histopathology. 2007 Jul; 51(1):54-62.
    View in: PubMed
    Score: 0.002
  148. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A. 2007 Jul 03; 104(27):11400-5.
    View in: PubMed
    Score: 0.002
  149. Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer. Mol Cancer Res. 2007 May; 5(5):485-96.
    View in: PubMed
    Score: 0.002
  150. PDGFR-alpha as a potential therapeutic target in uterine sarcomas. Gynecol Oncol. 2007 Mar; 104(3):524-8.
    View in: PubMed
    Score: 0.002
  151. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1356-65.
    View in: PubMed
    Score: 0.002
  152. Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8538-48.
    View in: PubMed
    Score: 0.002
  153. Angiography-proven liver metastases explain low efficacy of lymph node dissections in medullary thyroid cancer patients. Eur J Surg Oncol. 2005 Mar; 31(2):183-90.
    View in: PubMed
    Score: 0.002
  154. Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia. Gynecol Oncol. 2004 Jul; 94(1):204-7.
    View in: PubMed
    Score: 0.002
  155. Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers. Clin Cancer Res. 2003 Jun; 9(6):2267-76.
    View in: PubMed
    Score: 0.002
  156. Role of beta(3)-endonexin in the regulation of NF-kappaB-dependent expression of urokinase-type plasminogen activator receptor. J Cell Sci. 2002 Oct 15; 115(Pt 20):3879-88.
    View in: PubMed
    Score: 0.002
  157. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001 Aug; 7(8):2396-404.
    View in: PubMed
    Score: 0.001
  158. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol. 2001 Aug; 82(2):291-8.
    View in: PubMed
    Score: 0.001
  159. Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. J Biol Chem. 2001 Jul 13; 276(28):26340-8.
    View in: PubMed
    Score: 0.001
  160. Transient interaction of activated platelets with endothelial cells induces expression of monocyte-chemoattractant protein-1 via a p38 mitogen-activated protein kinase mediated pathway. Implications for atherogenesis. Cardiovasc Res. 2001 Jan; 49(1):189-99.
    View in: PubMed
    Score: 0.001
  161. Downregulation of a mitogen-activated protein kinase signaling pathway in the placentas of women with preeclampsia. Obstet Gynecol. 2000 Oct; 96(4):582-7.
    View in: PubMed
    Score: 0.001
  162. Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene. 2000 Jun 15; 19(26):3013-20.
    View in: PubMed
    Score: 0.001
  163. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor. J Biol Chem. 1999 Jun 04; 274(23):16377-86.
    View in: PubMed
    Score: 0.001
  164. [The clinical importance of keratin 18 in breast cancer]. Zentralbl Gynakol. 1999; 121(3):126-30.
    View in: PubMed
    Score: 0.001
  165. In vitro modulation of human melanoma cell invasion and proliferation by all-trans-retinoic acid. Melanoma Res. 1998 Jun; 8(3):211-9.
    View in: PubMed
    Score: 0.001
  166. [Juvenile aneuploid papillary cancer of the thyroid with pulmonary metastasis]. Orv Hetil. 1998 Mar 22; 139(12):687-90.
    View in: PubMed
    Score: 0.001
  167. Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades. Oncogene. 1997 Mar 27; 14(12):1481-93.
    View in: PubMed
    Score: 0.001
  168. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem. 1996 May 03; 271(18):10672-80.
    View in: PubMed
    Score: 0.001
  169. Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene. Anticancer Res. 1995 Jul-Aug; 15(4):1167-72.
    View in: PubMed
    Score: 0.001
  170. Keratin expression reveals mosaic differentiation in vaginal epithelium. Am J Obstet Gynecol. 1993 Dec; 169(6):1603-7.
    View in: PubMed
    Score: 0.001
  171. Physiological age-related changes: cross-sectional and longitudinal studies. Methods Inf Med. 1993 Apr; 32(3):252-4.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.